TSE:4507Pharmaceuticals
Shionogi’s New U.S. And China Drug Approvals Shift Growth Outlook
Shionogi (TSE:4507) has received U.S. FDA approval for XOCOVA (ensitrelvir) as the first oral antiviral for post exposure prophylaxis of COVID-19.
The company also secured regulatory approval in China for Naldemedine Tosilate to treat opioid induced constipation.
These approvals expand Shionogi's marketed portfolio across infectious disease and pain management related conditions.
For investors tracking Shionogi at a share price of ¥2,855.0, these dual approvals arrive after a mixed shorter...